Acurx Pharmaceuticals, Inc. ACXP
We take great care to ensure that the data presented and summarized in this overview for Acurx Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ACXP
View all-
Vanguard Group Inc Valley Forge, PA492KShares$1.06 Million0.0% of portfolio
-
Prospect Financial Services LLC Melville, NY273KShares$589,3560.55% of portfolio
-
Geode Capital Management, LLC Boston, MA116KShares$251,3200.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ57.3KShares$123,6600.0% of portfolio
-
State Street Corp Boston, MA43.5KShares$93,8860.0% of portfolio
-
Lpl Financial LLC Fort Mill, SC40.2KShares$86,9070.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA37.4KShares$80,8660.0% of portfolio
-
Morgan Stanley New York, NY26.4KShares$57,0260.0% of portfolio
-
Black Rock Inc. New York, NY18.7KShares$40,3660.0% of portfolio
-
Td Waterhouse Canada Inc. Toronto, A618.7KShares$40,2960.0% of portfolio
Latest Institutional Activity in ACXP
Top Purchases
Top Sells
About ACXP
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Insider Transactions at ACXP
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 19
2024
|
Carl Sailer Director |
BUY
Exercise of conversion of derivative security
|
Direct |
19,737
+14.92%
|
$59,211
$3.55 P/Share
|
|
Jan 03
2024
|
David P Luci President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
19,737
+1.85%
|
$59,211
$3.55 P/Share
|
|
Jan 03
2024
|
Robert J Deluccia Director |
BUY
Exercise of conversion of derivative security
|
Direct |
19,737
+2.01%
|
$59,211
$3.55 P/Share
|
|
Dec 22
2023
|
Robert J Deluccia Director |
SELL
Bona fide gift
|
Direct |
30,000
-3.09%
|
-
|
|
Dec 12
2023
|
Robert J Deluccia Director |
SELL
Bona fide gift
|
Direct |
40,000
-3.96%
|
-
|
|
Jul 27
2022
|
David P Luci President and CEO |
BUY
Open market or private purchase
|
Direct |
19,737
+1.88%
|
$59,211
$3.8 P/Share
|
|
Jul 27
2022
|
Robert J Deluccia Director |
BUY
Open market or private purchase
|
Direct |
19,737
+1.84%
|
$59,211
$3.8 P/Share
|
|
Jul 27
2022
|
Carl Sailer Director |
BUY
Open market or private purchase
|
Direct |
19,737
+17.54%
|
$59,211
$3.8 P/Share
|
|
Dec 02
2021
|
Robert J Deluccia Director |
SELL
Bona fide gift
|
Direct |
40,000
-3.81%
|
-
|
|
Nov 23
2021
|
Carl Sailer Director |
BUY
Open market or private purchase
|
Direct |
5,161
+6.6%
|
$20,644
$4.84 P/Share
|
|
Nov 19
2021
|
David P Luci President and CEO |
BUY
Open market or private purchase
|
Direct |
5,200
+0.51%
|
$20,800
$4.8 P/Share
|
|
Nov 19
2021
|
Robert J Deluccia Director |
BUY
Open market or private purchase
|
Direct |
5,034
+0.49%
|
$20,136
$4.9 P/Share
|
|
Jun 29
2021
|
Carl Sailer Director |
BUY
Open market or private purchase
|
Direct |
12,500
+15.54%
|
$75,000
$6.0 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 59.2K shares |
|---|
| Bona fide gift | 70K shares |
|---|